RU95114598A - MEANS FOR THE TREATMENT OF PURULENT INFLAMMATORY DISEASES - Google Patents

MEANS FOR THE TREATMENT OF PURULENT INFLAMMATORY DISEASES

Info

Publication number
RU95114598A
RU95114598A RU95114598/14A RU95114598A RU95114598A RU 95114598 A RU95114598 A RU 95114598A RU 95114598/14 A RU95114598/14 A RU 95114598/14A RU 95114598 A RU95114598 A RU 95114598A RU 95114598 A RU95114598 A RU 95114598A
Authority
RU
Russia
Prior art keywords
treatment
inflammatory diseases
anhydrous lanolin
pyobacteriophage
combined
Prior art date
Application number
RU95114598/14A
Other languages
Russian (ru)
Other versions
RU2105544C1 (en
Inventor
Т.Г. Нигматуллин
И.Х. Насибулин
Н.М. Якубенко
Р.С. Вискова
Ф.А. Байгузина
Original Assignee
Научно-производственное объединение "Иммунопрепарат"
Filing date
Publication date
Application filed by Научно-производственное объединение "Иммунопрепарат" filed Critical Научно-производственное объединение "Иммунопрепарат"
Priority to RU95114598A priority Critical patent/RU2105544C1/en
Priority claimed from RU95114598A external-priority patent/RU2105544C1/en
Publication of RU95114598A publication Critical patent/RU95114598A/en
Application granted granted Critical
Publication of RU2105544C1 publication Critical patent/RU2105544C1/en

Links

Claims (1)

Средство для лечения гнойно-воспалительных заболеваний на основе пиобактериофага комбинированного, содержащего стафилококковый, стрептококковый, коли, протейный, псевдомонас аэругиноза монофаги, хинозол, отличающееся тем, что оно содержит очищенный концентрат пиобактериофага комбинированного, альбумин, безводный ланолин, растительное масло при следующем соотношении компонентов, мас. %: очищенный концентрат пиобактериофага комбинированного, содержащий монофаги с литической активностью по Аппельману не менее 10-7 - 10-8: стафилококковый 1,8 - 3, стрептококковый 1,8 - 3, коли 1,8 - 3, протейный 1,8 - 3, псевдомонас аэругиноза 1,8 - 3, 1%-ный раствор хинозола 0,8 - 1,2, ланолин безводный 25 - 35, альбумин 1,8 - 2,0, масло растительное - до 100,0.Means for the treatment of purulent-inflammatory diseases based on combined pyobacteriophage, containing staphylococcal, streptococcal, coli, proteus, pseudomonas aeruginosa monophages, quinosol, characterized in that it contains a purified concentrate of pyobacteriophage combined, albumin, anhydrous lanolin, anhydrous lanolin, anhydrous lanolin, wt. %: purified concentrate of pyobacteriophage combined, containing monophages with Appelman lytic activity of at least 10 -7 - 10 -8 : staphylococcal 1.8 - 3, streptococcal 1.8 - 3, if 1.8 - 3, protean 1.8 - 3, pseudomonas aeruginosa 1.8 - 3, 1% quinosole solution 0.8 - 1.2, anhydrous lanolin 25 - 35, albumin 1.8 - 2.0, vegetable oil - up to 100.0.
RU95114598A 1995-08-14 1995-08-14 Agent for suppurative-inflammatory disease treatment RU2105544C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU95114598A RU2105544C1 (en) 1995-08-14 1995-08-14 Agent for suppurative-inflammatory disease treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU95114598A RU2105544C1 (en) 1995-08-14 1995-08-14 Agent for suppurative-inflammatory disease treatment

Publications (2)

Publication Number Publication Date
RU95114598A true RU95114598A (en) 1997-12-10
RU2105544C1 RU2105544C1 (en) 1998-02-27

Family

ID=20171320

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95114598A RU2105544C1 (en) 1995-08-14 1995-08-14 Agent for suppurative-inflammatory disease treatment

Country Status (1)

Country Link
RU (1) RU2105544C1 (en)

Similar Documents

Publication Publication Date Title
MX9706095A (en) Multifunctional enzyme.
CA2081482A1 (en) Method and composition for treatment of central nervous system disease states associated with abnormal amyloid beta protein molecular organization
RU93047799A (en) COMPOSITIONS CONTAINING RETAIC ACIDS AND TOKOFEROL
WO1995017165A3 (en) Tissue moisturizing and antimicrobial compositions
NZ332721A (en) Use of bactericidal/permeability increasing (BPI) protein sometimes in conjunction with a thrombolytic agent to treat thrombotic disorders
GR3025502T3 (en) Drugs, their manufacture, and their use as painkillers and/or to treat inflammations in humans and animals.
CA2260145A1 (en) Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1
MX9606450A (en) Benzimidazolone derivatives with central dopaminergic activity.
EP0249736A3 (en) Ointment for the treatment of skin diseases
AU3459689A (en) Treatment of skin disorders
EP1157698A3 (en) Treatment of inflammatory diseases with oxypurine nucleosides
CA2094347A1 (en) A method of producing a factor viii preparation
BR9712466A (en) Application of adamantanamines or compounds of similar structure to combat borne disease virus and for the prophylaxis and treatment of emotional diseases and other disorders linked to infections of human and animal bd virus
RU95114598A (en) MEANS FOR THE TREATMENT OF PURULENT INFLAMMATORY DISEASES
RU95114599A (en) Means for the treatment of streptococcal diseases
RU95114631A (en) MEANS FOR TREATING DISEASES COLI-INFECTED
EP0784983A3 (en) Use of extracellular hemoglobin
EP0301975A3 (en) Monomeric and/or oligomeric procyanidines for the treatment of parodontal diseases
RU97111238A (en) DRUG FOR TREATMENT OF PURULENT INFLAMMATORY DISEASES (ITS OPTIONS)
FR2686515B1 (en) USE OF NIOBIUM DERIVATIVES AS ACTIVE INGREDIENT OF MEDICINES USEFUL IN THE TREATMENT AND / OR PREVENTION OF CARBOHYDRATE AND / OR LIPID METABOLISM DISORDERS.
Dubois et al. In vitro activities of enoxacin and CI-934 against urinary tract and gastrointestinal tract pathogens.
RU96102110A (en) METHOD FOR PREVENTION AND TREATMENT OF CORNERAL ULCER
Trujillo et al. Safety and Efficacy of Netilmycin in Newborns With Serious Systemic Infections.
RU97110967A (en) MEASURES FOR FIGHTING BEES BACTERIOSIS
MA23429A1 (en) NOVEL GALENIC FORM OF 5-NITRO IMIDAZOLE DERIVATIVES EFFECTIVE FOR THE TREATMENT OF PARASITOSIS AND INFECTIONS OF THE WHOLE TRACTUS-GASTROINTESTINAL.